| Source: |
| Type: |
| Biological process in which epithelial cells lose their cell polarity and cell-cell adhesion properties and gain mesenchymal traits, such as increased motility and invasiveness. This process is pivotal during embryogenesis and wound healing. Hh signaling pathway is able to regulate the EMT. Snail, E-cadherin and N-cadherin, key components of EMT; EMT-related factors, E-cadherin, N-cadherin, vimentin; The hallmark of EMT is the upregulation of N-cadherin followed by the downregulation of E-cadherin. EMT is regulated by various signaling pathways, including TGF-β, Wnt, Notch, and Hedgehog pathways. Transcription factors such as Snail, Slug, Twist, and ZEB play critical roles in repressing epithelial markers (like E-cadherin) and promoting mesenchymal markers (like N-cadherin and vimentin). EMT is associated with increased tumor aggressiveness, enhanced migratory and invasive capabilities, and resistance to apoptosis. |
| 1118- | GSE, | Grape Seed Proanthocyanidins Inhibit Migration and Invasion of Bladder Cancer Cells by Reversing EMT through Suppression of TGF- β Signaling Pathway |
| - | in-vitro, | Bladder, | T24/HTB-9 | - | in-vitro, | Bladder, | 5637 |
| 1240- | GSE, | PACs, | Grape Seed Proanthocyanidins Inhibit Melanoma Cell Invasiveness by Reduction of PGE2 Synthesis and Reversal of Epithelial-to-Mesenchymal Transition |
| - | in-vitro, | Melanoma, | A375 | - | in-vitro, | Melanoma, | Hs294T |
| 1643- | HCAs, | Mechanisms involved in the anticancer effects of sinapic acid |
| - | Review, | Var, | NA |
| 1119- | HNK, | Honokiol inhibits epithelial—mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E‐cadherin axis |
| - | vitro+vivo, | BC, | NA |
| 1120- | HNK, | Honokiol suppresses renal cancer cells' metastasis via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties through modulating miR-141/ZEB2 signaling |
| - | vitro+vivo, | RCC, | NA |
| 2877- | HNK, | Targeting histone deacetylase-3 blocked epithelial-mesenchymal plasticity and metastatic dissemination in gastric cancer |
| - | in-vitro, | GC, | AGS |
| 2881- | HNK, | Honokiol Suppressed Pancreatic Cancer Progression via miR-101/Mcl-1 Axis |
| - | in-vitro, | PC, | PANC1 |
| 2882- | HNK, | Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling |
| - | in-vitro, | PC, | PANC1 |
| 2883- | HNK, | Honokiol targets mitochondria to halt cancer progression and metastasis |
| - | Review, | Var, | NA |
| 2884- | HNK, | Honokiol inhibits EMT-mediated motility and migration of human non-small cell lung cancer cells in vitro by targeting c-FLIP |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 |
| 2866- | HNK, | Honokiol and its analogues as anticancer compounds: Current mechanistic insights and structure-activity relationship |
| - | Review, | Var, | NA |
| 2864- | HNK, | Honokiol: A Review of Its Anticancer Potential and Mechanisms |
| - | Review, | Var, | NA |
| 2891- | HNK, | Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs |
| - | Review, | Var, | NA |
| 4688- | HNK, | Honokiol Suppresses Renal Cancer Cells’ Metastasis via Dual-Blocking Epithelial-Mesenchymal Transition and Cancer Stem Cell Properties through Modulating miR-141/ZEB2 Signaling |
| - | vitro+vivo, | RCC, | A498 |
| 4659- | HNK, | Honokiol Eliminates Human Oral Cancer Stem-Like Cells Accompanied with Suppression of Wnt/β-Catenin Signaling and Apoptosis Induction |
| - | in-vitro, | Oral, | NA |
| - | in-vitro, | BC, | SUM159 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | HS587T | - | in-vitro, | BC, | BT549 |
| 4640- | HT, | The anti-cancer potential of hydroxytyrosol |
| - | Review, | Var, | NA |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vitro, | BC, | SUM159 |
| 1168- | IVM, | SRF, | Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways |
| - | in-vitro, | HCC, | NA |
| 5115- | JG, | Natural Products to Fight Cancer: A Focus on Juglans regia |
| - | Review, | Var, | NA |
| 1266- | LE, | Glycyrrhizin suppresses epithelial-mesenchymal transition by inhibiting high-mobility group box1 via the TGF-β1/Smad2/3 pathway in lung epithelial cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | BEAS-2B |
| 1122- | LF, | MTX, | Lactoferrin Reverses Methotrexate Driven Epithelial Barrier Defect by Inhibiting TGF-β Mediated Epithelial to Mesenchymal Transition |
| - | in-vivo, | Colon, | Caco-2 |
| 1100- | LT, | Luteolin, a flavonoid, as an anticancer agent: A review |
| - | Review, | NA, | NA |
| 4687- | LT, | QC, | Dietary Flavonoids Luteolin and Quercetin Suppressed Cancer Stem Cell Properties and Metastatic Potential of Isolated Prostate Cancer Cells |
| - | in-vitro, | Pca, | DU145 |
| 2912- | LT, | Luteolin: a flavonoid with a multifaceted anticancer potential |
| - | Review, | Var, | NA |
| 2914- | LT, | Therapeutic Potential of Luteolin on Cancer |
| - | Review, | Var, | NA |
| 2919- | LT, | Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence |
| - | Review, | Var, | NA |
| 2916- | LT, | Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 1714- | Lyco, | Lycopene reduces ovarian tumor growth and intraperitoneal metastatic load |
| - | in-vitro, | Ovarian, | OV-MZ-6 | - | in-vivo, | NA, | NA |
| 1126- | Lyco, | Lycopene Inhibits Epithelial–Mesenchymal Transition and Promotes Apoptosis in Oral Cancer via PI3K/AKT/m-TOR Signal Pathway |
| - | vitro+vivo, | Oral, | NA |
| 4795- | Lyco, | Updates on the Anticancer Profile of Lycopene and its Probable Mechanism against Breast and Gynecological Cancer |
| - | Review, | BC, | NA |
| 4520- | MAG, | Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling |
| - | vitro+vivo, | PC, | PANC1 |
| 2376- | MET, | Metformin Inhibits Epithelial-to-Mesenchymal Transition of Keloid Fibroblasts via the HIF-1α/PKM2 Signaling Pathway |
| - | in-vitro, | Nor, | NA |
| 2371- | MET, | The role of pyruvate kinase M2 in anticancer therapeutic treatments |
| - | Review, | Var, | NA |
| 2377- | MET, | Metformin Inhibits TGF-β1-Induced Epithelial-to-Mesenchymal Transition via PKM2 Relative-mTOR/p70s6k Signaling Pathway in Cervical Carcinoma Cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Cerv, | SiHa |
| 2378- | MET, | Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway |
| - | in-vitro, | SCC, | CAL27 | - | in-vivo, | NA, | NA |
| 2384- | MET, | Integration of metabolomics and transcriptomics reveals metformin suppresses thyroid cancer progression via inhibiting glycolysis and restraining DNA replication |
| - | in-vitro, | Thyroid, | BCPAP | - | in-vivo, | NA, | NA | - | in-vitro, | Thyroid, | TPC-1 |
| 2386- | MET, | Mechanisms of metformin inhibiting cancer invasion and migration |
| - | Review, | Var, | NA |
| 1141- | Myr, | Myricetin: targeting signaling networks in cancer and its implication in chemotherapy |
| - | Review, | NA, | NA |
| 1799- | NarG, | Naringenin as potent anticancer phytocompound in breast carcinoma: from mechanistic approach to nanoformulations based therapeutics |
| - | Review, | NA, | NA |
| 1129- | NarG, | Naringenin Attenuated Prostate Cancer Invasion via Reversal of Epithelial-to-Mesenchymal Transition and Inhibited uPA Activity |
| - | in-vitro, | Pca, | PC3 |
| 5253- | NCL, | Niclosamide: Beyond an antihelminthic drug |
| - | Review, | Var, | NA |
| 6486- | Nimb, | Nimbolide: promising agent for prevention and treatment of chronic diseases |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4976- | Nimb, | Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition |
| - | vitro+vivo, | PC, | NA |
| 4977- | Nimb, | Nimbolide Inhibits SOD2 to Control Pancreatic Ductal Adenocarcinoma Growth and Metastasis |
| - | vitro+vivo, | PC, | AsPC-1 | - | in-vitro, | PC, | PANC1 |
| 4646- | OLEC, | Oleocanthal as a Multifunctional Anti-Cancer Agent: Mechanistic Insights, Advanced Delivery Strategies, and Synergies for Precision Oncology |
| - | Review, | Var, | NA |
| 3257- | PBG, | The Potential Use of Propolis as a Primary or an Adjunctive Therapy in Respiratory Tract-Related Diseases and Disorders: A Systematic Scoping Review |
| - | Review, | Var, | NA |
| 1673- | PBG, | An Insight into Anticancer Effect of Propolis and Its Constituents: A Review of Molecular Mechanisms |
| - | Review, | Var, | NA |
| 4922- | PEITC, | Phenethyl Isothiocyanate: A comprehensive review of anti-cancer mechanisms |
| - | Review, | Var, | NA |
| 4926- | PEITC, | PEITC inhibits the invasion and migration of colorectal cancer cells by blocking TGF-β-induced EMT |
| - | in-vitro, | CRC, | SW48 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:96 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid